Linda M. Rubinstein - Aug 3, 2023 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)

Role
Chief Financial Officer
Signature
Linda Rubinstein, by /s/ Ron A. Metzger, Attorney-in-Fact
Stock symbol
ADVM
Transactions as of
Aug 3, 2023
Transactions value $
$0
Form type
4
Date filed
9/5/2023, 05:14 PM
Previous filing
Jun 9, 2023
Next filing
Feb 14, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ADVM Stock Option (Right to Buy) Award $0 +850K $0.00 850K Aug 3, 2023 Common Stock 850K $2.10 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Non-Statutory Stock Option to purchase 850,000 shares granted under the Issuer's 2014 Equity Incentive Plan (the "Plan"), 25% vesting 6 months from the Reporting Person's first day of employment with the Issuer, and 17,708.33 shares vesting monthly thereafter for the next 36 months, subject to the Reporting Person's continued service with the Issuer on each such vesting date.